Review of upcoming and currently available anti-obesity drugs in Europe

Abstract

Obesity is a chronic metabolic disease currently holding status of an epidemic. Number of patients suffering from this condition has been steadily increasing for over 50 years. Complications and comorbidities related to obesity, such as hypertension, diabetes mellitus type 2, coronary artery disease and dyslipidemia are currently the main causes of death in Europe. Therefore, effective anti-obesity treatment as a pharmacological support for weight loss is highly recommended in overweight and obese patients as a therapeutic and preventive measure. This review focuses on selected therapeutic options available for clinicians in Europe.

Keywords

• obesity.
• pharmacology
• liraglutide
• semaglutide
• tirzepatide